Abstract
Importance The increasing incidence and prevalence of dengue in Latin America is well-documented. Historical case-control series also highlight that secondary infections are a risk factor for severe dengue, hospitalization, and death. This has generated alarm among some sectors of the population and the scientific community. However, there has been no examination based on the results of randomized clinical trials that analyzes the risk of severe events in individuals with and without prior dengue infection.
Objective To evaluate the association between serologically confirmed prior dengue infection (DVC) and the subsequent risk of DVC, severe dengue (DS), dengue hospitalization (DHOSP), dengue-related death, and all-cause mortality.
Methods A systematic review and meta-analysis were conducted following PRISMA guidelines. Studies were searched in PubMed, CINAHL, Medline, Cochrane Library, and Web of Science, including only phase III randomized clinical trials of vaccine efficacy with data on participants in the placebo groups and information on previous infections. Random-effects models were applied to calculate combined odds ratios (OR), and heterogeneity among studies was assessed.
Results A total of four studies corresponding to three phase III clinical trials were included. Participants with prior infection had a lower likelihood of developing DVC during follow-up (OR: 0.85; 95% CI: [0.75; 0.98]; p=0.024) and the same risk of dengue hospitalization as those without prior dengue (OR: 1.18; 95% CI: [0.92; 1.53]; p=0.198). However, they had a higher rate of DS during follow-up (OR: 2.91; 95% CI: [1.23; 6.87]; p=0.015). No dengue-related deaths were observed in any of the clinical trials during follow-up.
Conclusions Prior dengue infection significantly reduces the risk of DVC and increases the risk of DS, although it does not significantly affect the risk of dengue hospitalization or dengue-related death during follow-up. The findings of this study highlight the need to reconsider the value of prior infection as an independent risk factor.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
